A Phase 2 interventional study of Nivolumab and Cisplatin in Muscle Invasive Bladder Cancer, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-16.
Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 10 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 19th largest by enrollment, is one of 6 that started in 2018, is one of 13 in phase 2, and was the 6th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15 · Phase 3 4
First in 2015; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 76 across the 25 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
Masonic Cancer Center, University of Minnesota has 1 study filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing nivolumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06237920The Netherlands Cancer InstituteStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | 2026-12-01 |
| NCT03520491Memorial Sloan Kettering Cancer CenterA Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | 2027-01 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT02496208National Cancer Institute (NCI)Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC) prior to standard of care radical cystectomy. Patients will receive neoadjuvant treatment with nivolumab in combination with gemcitabine-cisplatin (GC) every 3 weeks for 4 treatment cycles over 12 weeks followed by standard of care radical cystectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Required initial laboratory values within 14 days of study enrollment:
Exclusion Criteria:
Ineligible to receive cisplatin by meeting one or more of the following criteria;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nivolumab · Drug: Cisplatin · Drug: Gemcitabine
Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
Also known as: Opdivo
Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
Also known as: Platinol
Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
Also known as: Gemzar
Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)
Incidence of Measurable Disease "pT" in the TNM staging system refers to the size and extend of the primary tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. pTa refers to noninvasive papillary carcinoma. pTis refers to carcinoma in situ (CIS) or a "flat tumor" stage. pN refers to lymph nodes. N0 mans cancer has not spread to nearby lymph nodes.
Time frame: Surgery Day 1
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment Day 1 of cycle 1
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment Day 8 of cycle 1
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment Day 1 of cycle 2
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treament day 8 of cycle 2
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment day 1 of cycle 3
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment day 8 of cycle 3
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment day 1 of cycle 4
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
Time frame: Treatment day 8 of cycle 4
Safety of Nivolumab With Gemcitabine/Cisplatin
Incidence of Adverse Events
Time frame: 30 Days +/- 7 Days after last chemotherapy
Safety of Nivolumab With Gemcitabine/Cisplatin
Incidence of Adverse Events
Time frame: 4 weeks post radical cystectomy
Count of Participants Experiencing Progression Free Survival (PFS)
Count of participants experiencing Progression Free Survival (PFS)
Time frame: Every 3 Months for 2 Years
| Milestone | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Started | 43 |
| Completed | 43 |
| Not completed | 0 |
Incidence of Measurable Disease "pT" in the TNM staging system refers to the size and extend of the primary tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. pTa refers to noninvasive papillary carcinoma. pTis refers to carcinoma in situ (CIS) or a "flat tumor" stage. pN refers to lymph nodes. N0 mans cancer has not spread to nearby lymph nodes.
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis) | 27 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1) | 7 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1) | 27 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2) | 18 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2) | 15 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3) | 16 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3) | 13 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4) | 8 |
Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4) | 11 |
Incidence of Adverse Events
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin | 5 |
Incidence of Adverse Events
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Safety of Nivolumab With Gemcitabine/Cisplatin | 24 |
Count of participants experiencing Progression Free Survival (PFS)
| Participants | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Count of Participants Experiencing Progression Free Survival (PFS) | 36 |
Collected over 120 days after last dose nivolumab. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab, Cisplatin, & Gemcitabine | 7/43 (16.3%) | 11/43 (25.6%) | 42/43 (97.7%) |
| Event | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| General disorders and administration site conditions - Other, specifyGeneral disorders | 2/43 |
| Thromboembolic eventVascular disorders | 2/43 |
| AnemiaBlood and lymphatic system disorders | 1/43 |
| DehydrationMetabolism and nutrition disorders | 1/43 |
| FatigueGeneral disorders | 1/43 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/43 |
| FeverGeneral disorders | 1/43 |
| HyponatremiaMetabolism and nutrition disorders | 1/43 |
| Nervous system disorders - Other, specifyNervous system disorders | 1/43 |
| Neutrophil count decreasedInvestigations | 1/43 |
| Event | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| NauseaGastrointestinal disorders | 31/43 |
| FatigueGeneral disorders | 30/43 |
| AnemiaBlood and lymphatic system disorders | 25/43 |
| ConstipationGastrointestinal disorders | 24/43 |
| Neutrophil count decreasedInvestigations | 20/43 |
| White blood cell decreasedInvestigations | 18/43 |
| HypertensionVascular disorders | 15/43 |
| General disorders and administration site conditions - Other, specifyGeneral disorders | 13/43 |
| Platelet count decreasedInvestigations | 13/43 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 13/43 |
| Age, Categorical(Participants) | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 21 |
| >=65 years | 22 |
| Sex/Gender, Customized(Participants) | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Male | 15 |
| Female | 26 |
| Unknown | 2 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 34 |
| Unknown or Not Reported | 8 |
| Race (NIH/OMB)(Participants) | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 31 |
| More than one race | 0 |
| Unknown or Not Reported | 12 |
| Region of Enrollment(participants) | Nivolumab, Cisplatin, & Gemcitabine |
|---|---|
| United States | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Jun 2020, 28 months.
Results were first posted in Dec 2021, 1 year 6 months after primary completion.
Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's 28 months is below that.
Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Cisplatin · Gemcitabine
Masonic Cancer Center, University of Minnesota →